REVIEW article
Front. Pharmacol.
Sec. Neuropharmacology
Bortezomib-induced peripheral neuropathy: from molecular mechanisms to clinical management
Provisionally accepted
- 1Tianjin University of Traditional Chinese Medicine, Tianjin, China
- 2Tianjin Medical University General Hospital, Tianjin, China
- 3Tianjin Medical University, Tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Bortezomib (BTZ) is a first-generation proteasome inhibitor that has shown significant efficacy in the treatment of multiple myeloma (MM), providing significant therapeutic benefits without severely compromising overall patient health. However, one of the most common and debilitating side effects associated with BTZ therapy is bortezomib-induced peripheral neuropathy (BIPN). This condition is the leading complication observed in patients undergoing BTZ treatment and has a profound impact on treatment regimens, often necessitating dose reductions or alterations in the dosing schedule. Despite the widespread recognition of BIPN, there is currently no universally accepted protocol for its prevention or management. Consequently, further exploration of the molecular mechanisms underlying BIPN is crucial to identify potential therapeutic targets. Establishing standardized, effective treatment strategies is also essential to improve patient outcomes. This review seeks to provide an in-depth overview of the current research on BIPN, covering its clinical presentation, potential pathophysiological mechanisms, and emerging therapeutic strategies. The aim is to offer valuable insights to support the development of novel therapeutic approaches and enhance clinical management of this challenging side effect.
Keywords: bortezomib-induced peripheral neuropathy, Neurotoxicity, neuropathic pain, clinicalsyndromes, Pathogenesis, therapeutic approaches
Received: 06 Oct 2025; Accepted: 03 Nov 2025.
Copyright: © 2025 Yan, Song, Zhang, Hu, Wang, Guo, Zhen, Ma and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lin Ma, malin419@163.com
Baoshan Liu, liubaoshan0821@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.